Guided Therapeutics (GTHP) Long-Term Debt Issuances (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Long-Term Debt Issuances for 13 consecutive years, with -$303000.0 as the latest value for Q4 2025.
- Quarterly Long-Term Debt Issuances fell 27.85% to -$303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $160000.0 through Dec 2025, up 113.33% year-over-year, with the annual reading at $160000.0 for FY2025, 113.33% up from the prior year.
- Long-Term Debt Issuances hit -$303000.0 in Q4 2025 for Guided Therapeutics, down from $108000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.4 million in Q3 2022 to a low of -$1.4 million in Q4 2022.
- Historically, Long-Term Debt Issuances has averaged $43900.0 across 4 years, with a median of $131000.0 in 2024.
- Biggest five-year swings in Long-Term Debt Issuances: surged 584.31% in 2022 and later decreased 27.85% in 2025.
- Year by year, Long-Term Debt Issuances stood at $204000.0 in 2021, then crashed by 784.31% to -$1.4 million in 2022, then surged by 83.02% to -$237000.0 in 2024, then dropped by 27.85% to -$303000.0 in 2025.
- Business Quant data shows Long-Term Debt Issuances for GTHP at -$303000.0 in Q4 2025, $108000.0 in Q3 2025, and $150000.0 in Q2 2025.